Hippocratic AI: Clinically Validated AI Agents for Healthcare Support in the US

Hippocratic AI developed generative AI agents for healthcare to assist with patient intake, scheduling, medication adherence monitoring, screening outreach, clinical trial support, adverse event detection, and escalation to human clinicians when necessary.

Organization
Hippocratic AI
Industry
Healthcare
Published
September 2025

Reported outcomes

12x

timeTime & speed

−30%time−360%time

Strategic outcomes

New product / capabilityLaunched clinically validated AI agentsNew product / capabilityExpanded clinical workflow supportScale & capacityAugmented healthcare staff capacityCustomer experience & trustImproved patient engagement and care

Catalog median for time & speed deployments: −60% across 728 reported metrics. Compare benchmarks →

Primary read

Use case focus

Showing 3 of 5

  • 1Patient Intake
  • 2Scheduling
  • 3Medication Adherence
Healthcare providers face challenges managing clinical interactions, patient outreach, follow-ups, treatment adherence, and health disparities.
Hippocratic AI uses Microsoft AI technology with a novel 4.1T+ parameter constellation architecture to create clinically validated AI agents. These agents assist in various clinical workflows without diagnosing or prescribing, augmenting healthcare staff capacity and patient engagement.
Achieved 12x average ROI, 30% reduction in readmission rates, 360% increase in chronic care management capacity, improved vaccination rates, and higher engagement with Spanish-speaking patients. Freed clinical staff time and increased patient care effectiveness.
Architecture

The solution uses a novel 4.1T+ parameter constellation architecture with specialized large parameter models clinically validated by a network of over 7K US licensed clinicians.

Sources & evidence1
Groundedness: 4/5

AI-generated summary. Verify important details with the linked sources before relying on this case.

Explore related AI use cases

Was this useful?

Community

Comments

No published comments yet.